[1] 郑黎黎,沈薇,熊玲.乙型肝炎病毒X蛋白表达与肝细胞脂肪变性的关系及其机制.中国生物制品学杂志,2010,23:186-190.
[2] 江萃英,曾维琼,陈压西,等.乙型肝炎病毒对肝脂肪变患者肝细胞固醇调节元件结合蛋白表达的影响.中华肝脏病杂志,2011,19:608-613.
[3] 施军平,范建高,武瑞,等.慢性乙型肝炎患者合并肝细胞脂肪变的发生率及其危险因素分析.中国肝脏病杂志,2008,16:519-523.
[4] Jarcuska P,Janicko M,Kruzliak P,et al.Hepatitis B virus infection in patients with metabolic syndrome:a complicated relationship. Results of a population based study. Eur J Intern Med,2014,25:286-291.
[5] Pais R,Rusu E,Ratziu V.The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin liver Dis,2014,18:165-178.
[6] Salvatore Petta,CalogeroCamma,Vito Di Marco,et al.Hepatic steatosis and insulin resistance are associated with severe brosisin patients with chronic hepatitis caused by HBV or HCV infection. Liver Int, 2011,31:507-515.
[7] 邹敏超.慢性乙肝合并脂肪肝应用拉米夫定治疗的病毒变异研究.佛山科学技术学院学报:自然科学版,2010,28:73-75.
[8] 张要栋,徐尧江,宋伟泉,等.肝脂肪变性对慢性乙型肝炎患者拉米夫定治疗临床疗效的影响. 中国医师杂志,2014,:62-65.
[9] Shi JP, Fan JG,Lou GQ, et al.Hepatic steatosis:a common reason for elevated alanine aminotransferase levels in HBsAg-positive chronic hepatitis B patients with low HBV DNA loads. Zhonghua Gan Zang Bing Za zhi,2008 Nov.16:8 18:22.
[10] 董红药,毖余强,王敬,等.慢性乙型肝炎合并脂肪肝对替比夫定疗效的影响.中国新药与临床杂志,2008,27:759-761.
[11] Jin X, Chen YP, Yang YD, et al. Association between hepatic steatosis and entecavir treatment failure in chinese patients with chronic hepatitis B. ploS one,2012, 7: e34198.
[12] 徐振华,腾菁,毛乾国,等.肝功能异常患者血清自身抗体的检测分析.实用医学杂志,2015,31:391-394.
[13] 王江滨,徐严,季尚纬.丙型肝炎合并自身免疫现象及其治疗. 中华传染病杂志,2009,27:58-61.
[14] 吴元凯,陈淑如,林国莉等. 核苷(酸)类似物治疗慢性HBV感染者至HBV DNA阴转后ALT异常的因素分析. 中山大学学报(医学科学版),2014,35:525-532.
[15] Liu S, Hao M,Ren Y, et al. Analysis of diagnosis and treatment towards CHB patients complicated with fatty liver with complete virological response while biochemical suboptimal response. Zhonghua Gan Zang Bing Za zhi,2015,23:333-338.
[16] Chi H, Arends P, Reijnders JG, et al. Flares during long-term entecavir therapy in chronic hepatitis B. J Gastroenterol Hepatol, 2016, 31: 1882-1887. |
